GMAB has been the subject of several other reports. Royal Bank of Canada initiated coverage on Genmab A/S in a research report on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective for the company. Guggenheim initiated coverage on Genmab A/S in a report on Monday, August 12th. They set a “buy” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Genmab A/S in a report on Monday, August 26th. Finally, Morgan Stanley initiated coverage on Genmab A/S in a report on Monday, August 12th. They set an “overweight” rating on the stock. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $23.00.
Shares of GMAB stock opened at $19.89 on Thursday. Genmab A/S has a 52 week low of $12.10 and a 52 week high of $21.45.
A hedge fund recently bought a new stake in Genmab A/S stock. Private Capital Group LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,680 shares of the company’s stock, valued at approximately $41,000. 0.83% of the stock is currently owned by institutional investors.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: What is the yield curve?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.